According to DelveInsight, Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2017-2030 owing to the expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira) and other during the forecast period, i.e., 2020-2030.
DelveInsight’s “Atopic Dermatitis (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the 7MM.
Geography Covered
Study Period: 2017-2030
DelveInsight’s Atopic Dermatitis (AD) market report gives a thorough understanding of the Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Atopic dermatitis, also known as atopic eczema, is a condition that results in itchy, scaly and red skin. It is an inflammatory skin disease which is a common recurrent form of skin allergy. Acute flare-ups of eczematous pruritic lesions mainly categorise atopic dermatitis over dry skin due to high levels of immunoglobulin E (IgE).
Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide insights about historical and current Atopic Dermatitis (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
DelveInsight analysts revealed that total Atopic dermatitis prevalent population in 7MM was estimated to be around 41,261,411 in 2017.
Moreover, a higher Atopic dermatitis prevalence is observed in the United States approximately 19,460,609 cases, when compared with other geographies in 7MM, i.e., EU5 countries and Japan.
Request for sample pages
Atopic Dermatitis Market
Atopic dermatitis market analysis by DelveInsight revealed that the total market size in 7 MM was estimated to be around USD 2422 Million in 2017.
According to DelveInsight, Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2017-2030 owing to the expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira) and other during the forecast period, i.e., 2020–2030.
The Atopic Dermatitis (AD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Atopic Dermatitis (AD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Atopic Dermatitis (AD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Report Highlights
Table of contents
*The table of contents is not exhaustive; the final content may vary.
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/